The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-tumor effect alone and in combination with radiotherapy

IntroductionThe ability to modulate and enhance the anti-tumor immune responses is critical in developing novel therapies in cancer. The Tumor Necrosis Factor (TNF) Receptor Super Family (TNFRSF) are potentially excellent targets for modulation which result in specific anti-tumor immune responses. C...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Jamie Frankish, Debayan Mukherjee, Erminia Romano, Katharina Billian-Frey, Matthias Schröder, Karl Heinonen, Christian Merz, Mauricio Redondo Müller, Christian Gieffers, Oliver Hill, Meinolf Thiemann, Jamie Honeychurch, Tim Illidge, Jaromir Sykora
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Frontiers Media S.A. 2023-05-01
Edice:	Frontiers in Immunology
Témata:	CD40 HERA-CD40L TNFRSF TRAF2 tumor micro environment (TME) antigen presenting cells
On-line přístup:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1160116/full
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!